Alzheimer’s Disease & IR

Insulin Resistance & Alzheimer's Disease — USA & UK 1975–2022

Insulin Resistance & Alzheimer's Disease

Prevalence trajectories in the USA and United Kingdom, 1975–2022. Of all the conditions in this series, Alzheimer's carries the most compelling emerging science: researchers now widely term it "Type 3 Diabetes" — a state in which brain cells become resistant to insulin, are progressively starved of glucose, and begin to die. Over 80% of Alzheimer's patients have Type 2 diabetes or abnormal blood glucose. Brain glucose metabolism begins declining 10–15 years before any symptoms appear — precisely the window where insulin resistance is detectable and reversible through lifestyle intervention.

Why the two curves don't track each other exactly — even when the correlation is very high:

The solid line shows the percentage of adults with insulin resistance across the entire population — everyone with measurable insulin resistance, regardless of what condition it causes them. Because insulin resistance is the upstream root cause of many different diseases — type 2 diabetes, fatty liver, cognitive decline, cardiovascular disease and more — this curve rises relatively gradually as it reflects a burden shared across all of those outcomes.

The dotted line shows the prevalence of the specific condition studied on this page — in this case, only the people for whom insulin resistance has expressed itself as that particular disease. This curve can rise more steeply because it captures decades of accumulated cases: someone may develop insulin resistance at 35 but not manifest this condition until their 50s, so even a modest early rise in insulin resistance translates into a much larger rise in diagnosed cases years later.

The r value (e.g. r = 0.97) is a correlation coefficient. It doesn't measure whether the two lines are the same height — it measures how consistently they move together over time. An r of 0.97 means that 97% of the rise in this condition over the past five decades is statistically explained by the parallel rise in insulin resistance.

What the r value tells you:
0.50–0.70 — Modest connection. The two trends are related but many other factors are involved.
0.70–0.90 — Strong connection. Insulin resistance is a major driver, alongside other contributing causes.
0.90 and above — Dominant connection. Insulin resistance accounts for the overwhelming majority of the trend. At this level, it is difficult to argue that other factors are primarily responsible. The values seen across these studies — consistently 0.90 to 0.97 — place insulin resistance firmly in this category for every condition shown.

United States

USA — Insulin Resistance vs Alzheimer's

1975 – 2022  |  % of population
Insulin Resistance (%)
Alzheimer's Prevalence (%)
United Kingdom

UK — Insulin Resistance vs Dementia

1975 – 2022  |  % of population
Insulin Resistance (%)
Dementia Prevalence (%)
r = 0.97
USA
IR ↔ Alzheimer's
r = 0.96
UK
IR ↔ Dementia
>80%
of Alzheimer's patients
have T2DM or abnormal glucose
10–15 yrs
brain glucose decline
before symptoms appear
Why the USA and UK percentages differ: The USA figure plots Alzheimer's disease specifically as a percentage of adults aged 65 and over, using Alzheimer's Association prevalence estimates (approximately 10.9% in 2022). The UK figure plots all-cause dementia as a percentage of adults aged 65 and over — around 7–8% — since the Alzheimer's Society reports total dementia prevalence rather than Alzheimer's alone (approximately 65% of UK dementia cases are Alzheimer's type, so the Alzheimer's-only figure would be around 5%). Both series have risen steadily in parallel with insulin resistance. The slightly different absolute values reflect both diagnostic classification differences and genuine population differences, not a fundamental discrepancy in the underlying trend.
Among the strongest mechanistic cases in this entire series — alongside Type 2 Diabetes: Insulin resistance impairs brain glucose uptake via disruption of PI3K/Akt and GLUT4 signalling, starving neurons of energy. Simultaneously, impaired insulin signalling reduces clearance of amyloid-beta plaques and promotes tau hyperphosphorylation — both primary pathological hallmarks of Alzheimer's. Chronic hyperinsulinaemia activates neuroinflammatory cascades and causes measurable hippocampal shrinkage. A 2025 PRISMA systematic review of 213 studies concluded insulin resistance is "a key pathological driver" of AD. A JAMA Neurology study found reduced brain glucose metabolism in people with mild insulin resistance who showed zero cognitive symptoms — confirming the critical pre-symptomatic window. The same integrated protocol that reverses peripheral insulin resistance (GAPS gut healing, constitutional nutrition, strategic intermittent fasting, Transcendental Meditation) directly addresses the upstream drivers of this neurodegeneration. Sources: de la Monte & Wands (2008); Frontiers Neuroscience (2021); PMC systematic review (2025); JAMA Neurology (2015).
Data sources
Alzheimer's USA — prevalence trend: Hebert LE et al. — Estimated Prevalence of Alzheimer's Disease (1980 baseline: 2.88M, Milbank Quarterly 1990). Hebert LE et al. — Alzheimer disease in the United States 2010–2050 estimated using the 2010 Census (4.7M in 2010, PMC3719424). Alzheimer's Association Facts & Figures 2024/2025: 6.9–7.2M, approximately 10.9% of adults aged 65+. Pre-1990 estimates back-projected from East Boston Senior Health Project (EBSHP) age-specific prevalence rates applied to US Census population data.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3719424/
https://www.alz.org/alzheimers-dementia/facts-figures
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13809
Dementia UK — prevalence trend: Alzheimer's Society UK — 982,000 with dementia in the UK (2024), rising to projected 1.4M by 2040 (Carnall Farrar 2024 commissioned report). Dementia Statistics Hub / Alzheimer's Research UK — historical and projected prevalence data. NHS Primary Care Dementia Data June 2024: 487,432 GP-recorded diagnoses. Pre-2000 estimates from Prince et al. World Alzheimer Report 2015 and Jorm AF global meta-analysis, applied to UK 65+ population.
https://www.alzheimers.org.uk/blog/how-many-people-have-dementia-uk
https://dementiastatistics.org/about-dementia/prevalence-and-incidence/
https://digital.nhs.uk/data-and-information/publications/statistical/primary-care-dementia-data/june-2024
Mechanistic evidence — insulin resistance drives Alzheimer's ("Type 3 Diabetes"): de la Monte SM & Wands JR — Alzheimer's Disease Is Type 3 Diabetes, Evidence Reviewed. Journal of Diabetes Science and Technology, PMC2769828. Frontiers in Neuroscience — Insulin Resistance Exacerbates Alzheimer Disease via Multiple Mechanisms (2021). PRISMA systematic review of 213 studies, Diabetology & Metabolic Syndrome (August 2025), PMC12382249: "insulin resistance was consistently identified as a key pathological driver." Willette AA et al. — Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease, JAMA Neurology (2015).
https://pmc.ncbi.nlm.nih.gov/articles/PMC2769828/
https://pmc.ncbi.nlm.nih.gov/articles/PMC12382249/
https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2021.687157/full
https://jamanetwork.com/journals/jamaneurology/fullarticle/2398420
Insulin Resistance USA & UK: NHANES III 1988–94; NHANES 1999–2018 (Hirode & Wong, JAMA 2020); NHS Health Survey England; GBD 2019 metabolic risk; Diabetes UK; Frontiers meta-analysis 2025.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11601873/
https://www.diabetesuk.org/professionals/position-statements-reports/statistics/
Scroll to Top
MENU
For Radiant Health